SCHEMBL4130087

SCHEMBL4130087

Cc1ccc(-n2nc(CCNC(=O)O)cc2S(=O)(=O)c2ccc(Cl)nc2)c(F)c1

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.35
KMT2A Q03164 2/20 0.34
MEN1 O00255 1/20 0.34
GAA P10253 1/20 0.34
KDM4E B2RXH2 1/20 0.34
CNR1 P21554 7/20 0.34
NAMPT P43490 3/20 0.33
CYP2C9 P11712 1/20 0.33
CNR2 P34972 3/20 0.33
KCNQ3 O43525 1/20 0.33
KCNQ2 O43526 1/20 0.33
THRB P10828 1/20 0.32
CYP2D6 P10635 1/20 0.31
NPC1 O15118 1/20 0.31
RAB9A P51151 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
HCRTR1 O43613 1/20 0.31
HCRTR2 O43614 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4131275 0.93 ALDH1A1 (0.35) ALDH1A1KMT2AMEN1GAAKDM4E
SCHEMBL4130741 0.92 CNR1 (0.39) ALDH1A1GAACNR1NAMPTCYP2C9
SCHEMBL4134998 0.91 NAMPT (0.38) ALDH1A1CNR1NAMPTCYP2C9SMN1; SMN2
SCHEMBL4130559 0.89 GAA (0.39) ALDH1A1KMT2AMEN1GAANAMPT
SCHEMBL4131518 0.88 SCN9A (0.37) KMT2AMEN1GAAKDM4ECNR1
SCHEMBL3812573 0.87 KCNQ3 (0.36) ALDH1A1GAAKDM4ECNR1NAMPT
SCHEMBL4131144 0.86 NAMPT (0.37) ALDH1A1KMT2AGAAKDM4ENAMPT
SCHEMBL4130781 0.86 ALDH1A1 (0.35) ALDH1A1GAAKDM4ECNR1NAMPT
SCHEMBL4139322 0.86 GAA (0.36) KMT2AGAAKDM4ENAMPTCYP2C9
SCHEMBL4118159 0.85 GAA (0.35) ALDH1A1KMT2AMEN1GAAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2190822-B1 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS TAKEDA PHARMACEUTICAL (JP) 2014-12-31 EP disclosed
US-20090156642-A1 5-Membered heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156642-A1 5-Membered heterocyclic compound CEL, PGA5, COG5 ALDH1A1 1497/4885KMT2A 4776/4885MEN1 1910/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.